RBC Capital maintains Kymera Therapeutics at Sector Perform, raises price target to $116 from $112
Less than 1 min read
RBC Capital maintained Kymera Therapeutics at Sector Perform and raised its price target to $116 from $112, a 3.6% increase.
The price target implies a downside of 5.4% from the Oct 29 close of $122.60.
Recent analyst actions on Kymera Therapeutics
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | BTIG | Maintains | Buy | $139 |
| Oct 27 | Morgan Stanley | Maintains | Overweight | $146 |
| Oct 9 | Raymond James | Initiates Coverage On | Outperform | $140 |
| Oct 5 | Citigroup | Maintains | Buy | $150 |
Across the four most recent analyst notes published on Kymera Therapeutics over the past 30 days, price targets range from $139 to $150.
Explore more price target data and ratings for Kymera Therapeutics on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
Read the full article
Get unlimited access to analyst updates and ...